Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259334 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
A Phase 3 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 380
- Enrollment target
NCT03259334 is a Phase 3 study that was terminated before completion, run by Shire. The registered enrollment target is 380 participants.
The verdict
NCT03259334, a Phase 3 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 380 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of participant-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).
Interventions
- OTHER Placebo
- DRUG Ontamalimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2018-02-09 |
| Est. Completion | 2020-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03259334
The ClinicalTrials.gov registry entry for NCT03259334 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03259334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03259334 about?
NCT03259334 is a clinical study titled "Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis". The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of participant-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).
What is the current status of trial NCT03259334?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 380 participants. The study started on 2018-02-09. Estimated completion is 2020-10-23.
What interventions are being tested in trial NCT03259334?
The interventions under investigation include: Placebo (OTHER), Ontamalimab (DRUG).
Who is sponsoring clinical trial NCT03259334?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.